Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 807 results for "daiichi sankyo"

DS-8201 Fast-Tracked for HER2+ Metastatic Breast Cancer
Renal & Urology News

61 images for daiichi sankyo

Ariva.de, 2 weeks ago
World Pharma News, 1 month ago
Pharma Letter, 1 month ago
Livemint.com, 1 month ago
Money Control, 1 month ago
Scrip Intelligence, 1 month ago
Pharmaceutical Tech.com, 1 month ago
United News of India, 1 month ago
Livemint.com, 1 month ago
European Pharmaceutical Review, 1 month ago

Daiichi case: Delhi HC to hear main arguments in March

NEW DELHI: The Delhi High Court will hear the main arguments in Daiichi Sankyo's case against former Ranbaxy promoters Malvinder and Shivinder Singh in March 2017. This includes the Singh brothers arguments challenging the Japanese drug maker's ...
 Economic Times1 week ago Former Ranbaxy promoter Shivinder Singh to submit asset declarations to Delhi HC within three days  Business Standard1 week ago
Livemint.com

Sun Pharma launches authorized generics of 4 Daiichi Sankyo's drugs in US

Sun Pharma launches generics of all strengths of Benicar, Benicar HCT, Azor and Tribenzor tablets in US markets Mumbai: Sun Pharmaceutical Industries Ltd, the world's fifth largest generic drug company, has launched authorized generics of four ...
 Livemint.com1 month ago Sun Pharma launches four authorized generics for Benicar, Benicar HCT, Azor & Tribenzor of Daiichi Sankyo  PharmaBiz1 month ago

Daiichi Sankyo, Inspirion collaborate to commercialise MorphaBond formulated with SentryBond abuse-deterrent technology

Daiichi Sankyo, Inc. and Inspirion Delivery Sciences LLC (Inspirion) have entered into a strategic collaboration agreement in the US to commercialize FDA-approved MorphaBond (morphine sulfate) extended-release tablets, CII. The agreement also ...
 PharmaBiz1 month ago Daiichi Sankyo & Inspirion Delivery Sciences Announce Licensing Agreement  Drug Development & Delivery1 month ago BRIEF-Daiichi Sankyo Co and Inspirion Delivery Sciences LLC Announce U.S. Licensing Agreement for MorphaBond  Reuters UK1 month ago Daiichi Sankyo and Inspirion Delivery Sciences Announce U.S. Licensing Agreement for MorphaBond Formulated with SentryBond Abuse-Deterrent Technology  FirstWord Pharma1 month ago
[x]  
Pharmaceutical Tech.com

Ajanta Pharma launches BP lowering tablets in US

The company's product is a generic version of Daiichi Sankyo's Azor tablets Drug firm Ajanta Pharma has launched blood pressure lowering tablets in the US market. After the approval of the United States Food and Drug Administration (US FDA), the ...
 Express Pharma1 month ago Sun Pharma launches generic versions of Daiichi Sankyo medicines in US  Business Line1 month ago Sun Pharmaceutical launches 4 generics in US  India Infoline1 month ago Sun Pharma launches blood pressure drugs in US  Business Standard1 month ago
[x]  
Ariva.de

Daiichi Sankyo webcast presentation now available for on-demand viewing: dbVIC - Deutsche Bank ADR Virtual Investor Conference

Company invites individual and institutional investors, as well as advisors, to log-on to view the presentation TOKYO, Nov. 21, 2016 /CNW/ --Daiichi Sankyo Co., Ltd (JP: 4568.T, OTC: DSNKY) based in Tokyo, and focused on pharmaceutical business, ...
 4 Traders2 weeks ago Daiichi Sankyo to present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference on Thursday, November 17th, 2016  International Business Times3 weeks ago DAIICHI SANKYO : to present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference on Thursday, November 17th, 2016  4 Traders3 weeks ago
[x]  

Pieris Pharmaceuticals to Receive GLP Tox Milestone Payment in Daiichi Sankyo Collaboration

BOSTON, MA--(Marketwired - October 26, 2016) - Pieris Pharmaceuticals, Inc. ( NASDAQ: PIRS ), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ® technology platform for cancer and other ...
 Minyanville1 month ago BRIEF-Pieris Pharmaceuticals to receive GLP Tox payment in Daiichi Sankyo collaboration  Reuters UK1 month ago PIERIS PHARMACEUTICALS : to Receive GLP Tox Milestone Payment in Daiichi Sankyo Collaboration  4 Traders1 month ago PIERIS PHARMACEUTICALS, INC. (NASDAQ : PIRS) Files An 8-K Reports Financial Results And Provides Corporate Update For The Third Quarter Ended September 30, 2016  4 Traders3 weeks ago
[x]  

Daiichi Sankyo Announces New Subgroup Analyses of Once-Daily SAVAYSA® (edoxaban) in Patients with Non-Valvular Atrial Fibrillation to be Presented at AHA Scientific Sessions 2016

PARSIPPANY, N.J., Nov. 7, 2016 /PRNewswire/ -- ., (hereafter, Daiichi Sankyo) today announced the presentation of six abstracts at the American Heart Association (AHA) Scientific Sessions 2016, November 12-16, New Orleans, Louisiana. A new subgroup ...
 International Business Times1 month ago
[x]  

Daiichi Sankyo : Announces Phase 3 Clinical Trial (PRASTRO-I Study, PRASTRO-II Study) Results for Prasugrel Antiplatelet Agent for Patients with Ischemic Cerebrovascular Disease

Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Joji Nakayama, Representative Director, President and CEO (Code no.: 4568, First Section, Tokyo Stock Exchange) Please address inquiries to Noriaki Ishida, Executive Officer, Vice ...
 4 Traders1 month ago DAIICHI SANKYO : ENLIVEN Phase 3 Study of Pexidartinib in Tenosynovial Giant Cell Tumor (TGCT) Will Continue to Completion Following Enrollment Discontinuation  4 Traders1 month ago Daiichi Sankyo announces phase 3 trial results for prasugrel antiplatelet agent for ischemic cerebrovascular disease patients  PharmaBiz1 month ago

Torrent Pharmaceuticals Ltd. v. Daiichi Sankyo Inc.; Alembic Pharmaceuticals Ltd. v. Daiichi Sankyo Co. Ltd; Aurobindo Pharmaceuticals Ltd. v. Daiichi Sankyo Inc.

N.D. Ill. (2016) Fitzpatrick Obtains Dismissal on Behalf of Daiichi Sankyo of Three Generic Drug Companies Declaratory Judgment Actions On July 25, 2016, Fitzpatrick succeeded in obtaining dismissal of complaints brought by Torrent, Alembic ...
 Fitzpatrickcella.com2 weeks ago Torrent Pharmaceuticals Ltd. et al v. Daiichi Sankyo Co., Ltd., et al  JD Supra3 weeks ago Daiichi Sankyo Healthcare Co Ltd in Consumer Health (Japan)  MarketResearch.com3 weeks ago Portola broadens AndexXa partnership with Daiichi  BioPharma Dive1 month ago
[x]  
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less